Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis : Issues to Consider.
Myelin morphology and axon pathology in demyelination during experimental autoimmune encephalomyelitis.
Risk stratification and mitigation in multiple sclerosis.
Immune-mediated inflammatory diseases: progress in molecular pathogenesis and therapeutic strategies.
Iron chelation and multiple sclerosis.
Toll-like receptor signaling directly increases functional IL-17RA expression in neuroglial cells.
TIRC7 and HLA-DR axis contributes to inflammation in multiple sclerosis.
Diaphragm breathing movement measurement using ultrasound and radiographic imaging: a concurrent validity.
Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development.
Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis? A single-blind randomized controlled trial.
Update in vitamin D and multiple sclerosis.
Hydration status substantially affects chronic cerebrospinal venous insufficiency assessments.
Tract-specific white matter correlates of fatigue and cognitive impairment in benign multiple sclerosis.
Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.
Symptoms Related to Tumor Necrosis Factor Receptor 1-associated Periodic Syndrome, Multiple Sclerosis, and Severe Rheumatoid Arthritis in Patients Carrying the TNF Receptor Superfamily 1A D12E/p.Asp41Glu Mutation.
Two assessments to evaluate imagery ability: translation, test-retest reliability and concurrent validity of the German KVIQ and Imaprax.
Can we predict the evolution of an unpredictable disease like multiple sclerosis?
Serum Levels of Biomarkers of Immune Activation and Associations With Neurological Impairment in Relapsing-Remitting Multiple Sclerosis Patients During Remission.
Aquaporin-4 autoimmunity in a child without optic neuritis and myelitis.
Vitamin D receptor biochemical and genetic profiling and HLA-class II genotyping among Lebanese with multiple sclerosis - A pilot study.
In vivo evidence of hippocampal dentate gyrus expansion in multiple sclerosis.
Feasibility of the Use of Combinatorial Chemokine Arrays to Study Blood and CSF in Multiple Sclerosis.
Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients.
Methionyl-tRNA Formyltransferase (MTFMT) Deficiency Mimicking Acquired Demyelinating Disease.
Differential Sox10 genomic occupancy in myelinating glia.
Pages
« first
‹ previous
…
412
413
414
415
416
417
418
419
420
…
next ›
last »